Nuclear Medicine: Page 15

PSMA-PET shows value in primary staging of prostate cancer

By Will Morton

Prostate-specific membrane antigen (PSMA) PET/CT imaging can reveal metastatic bone cancer lesions in prostate cancer patients that may be undetected by conventional bone scintigraphy, according to a group in the Netherlands.

January 5, 2023

NorthStar and Inhibrx ink deal on radiopharmaceutical development

By AuntMinnie.com staff writers

NorthStar Medical Radioisotopes and biopharmaceutical company Inhibrx have inked a collaboration agreement for the development and production of new radiopharmaceuticals.

January 3, 2023

Fast acquisition techniques cut SPECT/CT bone scan times by half

By Will Morton

Whole-body SPECT/CT bone scan times to detect metastatic tumors in prostate cancer patients could be cut by half with the use of faster acquisition techniques, according to a study published December 12 in EJNMMI Physics.

December 18, 2022

Companies ink deal to develop OncoFAP-23

By AuntMinnie.com staff writers

Philochem has signed agreements with Seibersdorf Laboratories and Isotopia Molecular Imaging to develop its lutetium-177 OncoFAP-23 radiopharmaceutical for cancer treatment.

December 13, 2022

FBPA-PET can differentiate between malignant and benign lesions

By Will Morton

PET/CT imaging with a boron-based radiotracer is superior to that with standard F-18 FDG for differentiating malignant from benign lesions, according to a study published December 5 in Annals of Nuclear Medicine.

December 7, 2022

11 organizations join IAEA's Rays of Hope initiative

By AuntMinnie.com staff writers

The International Atomic Energy Agency (IAEA) has signed on 11 of the largest professional societies in cancer care to help improve access to radiotherapy worldwide through its Rays of Hope initiative.

December 6, 2022

3D printing technology could increase Mo-99 production

By Will Morton

Researchers at the National Centre for Nuclear Research in Swierk, Poland, have secured a patent for the use of 3D printing technology to increase production of molybdenum-99 (Mo-99) for medical imaging.

December 5, 2022

GE leans into improving patient outcomes, healthcare efficiency

By Erik L. Ridley and Kate Madden Yee

CHICAGO - At this year's RSNA meeting, GE Healthcare is focusing on two goals: improving patient outcomes and boosting the efficiency of the healthcare enterprise. Promotion of these themes comes just weeks before GE is set to spin off its healthcare division into a standalone firm to be called GE HealthCare, which it plans to do in January.

November 28, 2022

Road to RSNA 2022: Molecular Imaging Preview

By Will Morton

This year's nuclear medicine and molecular imaging program at RSNA 2022 resounds with the impact of theranostics on the lives of patients with prostate cancer, with prostate-specific membrane antigen PET imaging taking center stage. Organizers even saw fit to title one scientific session "Prostate and Theranostics Potpourri."

November 21, 2022

NorthStar to build a new development and manufacturing services unit

By AuntMinnie.com staff writers

NorthStar Medical Radioisotopes plans to expand its business with a new radiopharmaceutical Contract Development and Manufacturing Organization services unit it will build on its Beloit, WI, campus.

November 14, 2022

Predicting outcomes post coronary artery surgery: SPECT or angio?

By Will Morton

SPECT myocardial perfusion imaging may be a better approach than coronary angiography for predicting survival of patients after coronary artery bypass, according to a study published November 9 in The Annals of Thoracic Surgery.

November 13, 2022

Nuclear reactor inspections impact Mo-99 supplies

By AuntMinnie.com staff writers

A shortage in global supplies of molybdenum-99 (Mo-99) and iodine-131 is expected due to a mechanical failure at Belgium's BR2 reactor in Mol, according to a report by Nuclear Medicine Europe.

October 31, 2022

Previous Page

Page 15 of 438

Next Page